Literature DB >> 16237225

A case of solitary subependymal giant cell astrocytoma: two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism.

Tomotsugu Ichikawa1, Akiko Wakisaka, Shigeru Daido, Soichiro Takao, Takashi Tamiya, Isao Date, Shoichi Koizumi, Yo Niida.   

Abstract

Subependymal giant cell astrocytoma (SEGA) is a unique brain tumor arising in tuberous sclerosis complex (TSC), an autosomal dominant inherited phacomatosis. There are several case reports of solitary SEGA without any other manifestations of TSC. Usually these cases are thought to be forme fruste of TSC due to somatic mosaicism. However, no previous reports have used molecular methodology to fully investigate mutations in TSC genes or the possibility of somatic mosaicism. Here, we report a 20-year-old woman with a brain tumor. Pathological diagnosis was consistent with SEGA, but comprehensive clinical screening found no other lesions indicative of TSC. Molecular analysis of the tumor revealed loss of heterozygosity and allelic mutation (5228G>A, R1743Q) of TSC2. To detect the small fraction of mosaic mutation in somatic cells, we developed a highly sensitive new method: triple-nested polymerase chain reaction-restriction fragment length polymorphism. The identical TSC2 missense mutation was not detected in any other tissues from the same patient, including peripheral blood, buccal mucosa, urinary sediment, nail, and hair. According to these results, this patient should be considered as having SEGA that developed from two somatic hit mutations in TSC2, rather than being a TSC2 patient with a very small fraction of somatic mosaicism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237225      PMCID: PMC1888498          DOI: 10.1016/S1525-1578(10)60586-7

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  28 in total

1.  Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis.

Authors:  J Kwiatkowska; J Wigowska-Sowinska; D Napierala; R Slomski; D J Kwiatkowski
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

2.  Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis.

Authors:  A Astrinidis; L Khare; T Carsillo; T Smolarek; K S Au; H Northrup; E P Henske
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

3.  Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis.

Authors:  Y Niida; N Lawrence-Smith; A Banwell; E Hammer; J Lewis; R L Beauchamp; K Sims; V Ramesh; L Ozelius
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

4.  High rate of mosaicism in tuberous sclerosis complex.

Authors:  S Verhoef; L Bakker; A M Tempelaars; A L Hesseling-Janssen; T Mazurczak; S Jozwiak; A Fois; G Bartalini; B A Zonnenberg; A J van Essen; D Lindhout; D J Halley; A M van den Ouweland
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

5.  High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination.

Authors:  P K Gupta; A Sahota; S A Boyadjiev; S Bye; C Shao; J P O'Neill; T C Hunter; R J Albertini; P J Stambrook; J A Tischfield
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

6.  Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.

Authors:  M van Slegtenhorst; R de Hoogt; C Hermans; M Nellist; B Janssen; S Verhoef; D Lindhout; A van den Ouweland; D Halley; J Young; M Burley; S Jeremiah; K Woodward; J Nahmias; M Fox; R Ekong; J Osborne; J Wolfe; S Povey; R G Snell; J P Cheadle; A C Jones; M Tachataki; D Ravine; J R Sampson; M P Reeve; P Richardson; F Wilmer; C Munro; T L Hawkins; T Sepp; J B Ali; S Ward; A J Green; J R Yates; J Kwiatkowska; E P Henske; M P Short; J H Haines; S Jozwiak; D J Kwiatkowski
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

7.  Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions.

Authors:  E P Henske; B W Scheithauer; M P Short; R Wollmann; J Nahmias; N Hornigold; M van Slegtenhorst; C T Welsh; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

8.  Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.

Authors:  T A Smolarek; L L Wessner; F X McCormack; J C Mylet; A G Menon; E P Henske
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

9.  Exon scanning of the entire TSC2 gene for germline mutations in 40 unrelated patients with tuberous sclerosis.

Authors:  R L Beauchamp; A Banwell; P McNamara; M Jacobsen; E Higgins; H Northrup; P Short; K Sims; L Ozelius; V Ramesh
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

Review 10.  Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria.

Authors:  E S Roach; M R Gomez; H Northrup
Journal:  J Child Neurol       Date:  1998-12       Impact factor: 1.987

View more
  13 in total

1.  Renal angiomyolipoma (AML) harboring a missense mutation of TSC2 with copy-neutral loss of heterozygosity (CN-LOH).

Authors:  Masashi Idogawa; Tokimasa Hida; Toshiaki Tanaka; Noriaki Ohira; Shoichiro Tange; Yasushi Sasaki; Hisashi Uhara; Naoya Masumori; Takashi Tokino; Hiroshi Natori
Journal:  Cancer Biol Ther       Date:  2019-12-17       Impact factor: 4.742

Review 2.  The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective.

Authors:  Romina Moavero; Mariangela Pinci; Roberta Bombardieri; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2011-02-09       Impact factor: 1.475

3.  Late Manifestation of Subependymal Giant Cell Astrocytoma With Hydrocephalus in an Adult Patient With Tuberous Sclerosis Complex.

Authors:  Sarah Zaher Addeen; Lilyan Bou Yehia; Lubna Aburas; Mhd Firas Safadi
Journal:  Cureus       Date:  2022-08-26

Review 4.  The molecular biology of WHO grade I astrocytomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

Review 5.  Subependymal giant cell astrocytoma: current concepts, management, and future directions.

Authors:  Taohui Ouyang; Na Zhang; Thomas Benjamin; Long Wang; Jiantong Jiao; Yiqing Zhao; Jian Chen
Journal:  Childs Nerv Syst       Date:  2014-02-19       Impact factor: 1.475

Review 6.  A case of subependymal giant cell astrocytoma without tuberous sclerosis complex and review of the literature.

Authors:  Michael O'Rawe; Arjun S Chandran; Stuti Joshi; Alexandre Simonin; Jason M Dyke; Sharon Lee
Journal:  Childs Nerv Syst       Date:  2020-08-17       Impact factor: 1.475

Review 7.  Advances in the management of subependymal giant cell astrocytoma.

Authors:  Thomas L Beaumont; David D Limbrick; Matthew D Smyth
Journal:  Childs Nerv Syst       Date:  2012-05-05       Impact factor: 1.475

8.  Identification of TSC1 or TSC2 mutation limited to the tumor in three cases of solitary subependymal giant cell astrocytoma using next-generation sequencing technology.

Authors:  Martine Fohlen; Ines Harzallah; Marc Polivka; Fabienne Giuliano; Linda Pons; Nathalie Streichenberger; Georg Dorfmüller; Renaud Touraine
Journal:  Childs Nerv Syst       Date:  2020-02-26       Impact factor: 1.475

9.  Molecular and clinical analyses of 84 patients with tuberous sclerosis complex.

Authors:  Chia-Cheng Hung; Yi-Ning Su; Shu-Chin Chien; Horng-Huei Liou; Chih-Chuan Chen; Pau-Chung Chen; Chia-Jung Hsieh; Chih-Ping Chen; Wang-Tso Lee; Win-Li Lin; Chien-Nan Lee
Journal:  BMC Med Genet       Date:  2006-09-18       Impact factor: 2.103

10.  Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model.

Authors:  N Lozovaya; S Gataullina; T Tsintsadze; V Tsintsadze; E Pallesi-Pocachard; M Minlebaev; N A Goriounova; E Buhler; F Watrin; S Shityakov; A J Becker; A Bordey; M Milh; D Scavarda; C Bulteau; G Dorfmuller; O Delalande; A Represa; C Cardoso; O Dulac; Y Ben-Ari; N Burnashev
Journal:  Nat Commun       Date:  2014-08-01       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.